Wall Street analysts expect that Dynavax Technologies Corporation (NASDAQ:DVAX) will report sales of $37.77 million for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Dynavax Technologies’ earnings, with estimates ranging from $530,000.00 to $75.00 million. Dynavax Technologies posted sales of $7.29 million in the same quarter last year, which would indicate a positive year-over-year growth rate of 418.1%. The business is scheduled to announce its next quarterly earnings results on Monday, March 12th.

According to Zacks, analysts expect that Dynavax Technologies will report full-year sales of $37.77 million for the current fiscal year, with estimates ranging from $1.31 million to $75.31 million. For the next fiscal year, analysts expect that the company will report sales of $45.40 million per share, with estimates ranging from $39.78 million to $51.01 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Dynavax Technologies.

Dynavax Technologies (NASDAQ:DVAX) last released its earnings results on Friday, November 3rd. The biopharmaceutical company reported ($0.38) EPS for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.15. Dynavax Technologies had a negative return on equity of 65.97% and a negative net margin of 1,177.60%. The firm had revenue of $0.05 million for the quarter, compared to analysts’ expectations of $0.28 million. During the same period in the prior year, the firm posted ($0.90) earnings per share. The company’s quarterly revenue was down 68.8% on a year-over-year basis.

DVAX has been the topic of several recent analyst reports. Royal Bank Of Canada reaffirmed a “buy” rating and set a $26.00 price objective on shares of Dynavax Technologies in a research report on Friday, September 1st. Cowen reissued a “buy” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Friday, November 3rd. Cantor Fitzgerald initiated coverage on Dynavax Technologies in a report on Friday, September 15th. They issued an “overweight” rating and a $24.00 target price on the stock. ValuEngine raised Dynavax Technologies from a “sell” rating to a “hold” rating in a report on Thursday, September 7th. Finally, William Blair reissued an “outperform” rating and issued a $30.00 target price on shares of Dynavax Technologies in a report on Wednesday, August 9th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and five have issued a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $25.17.

Shares of Dynavax Technologies (NASDAQ:DVAX) opened at $17.75 on Tuesday. Dynavax Technologies has a 12-month low of $3.70 and a 12-month high of $24.45.

A number of institutional investors and hedge funds have recently modified their holdings of the stock. GMT Capital Corp raised its stake in Dynavax Technologies by 1.7% during the 3rd quarter. GMT Capital Corp now owns 3,057,437 shares of the biopharmaceutical company’s stock valued at $65,735,000 after purchasing an additional 52,300 shares during the period. Vanguard Group Inc. grew its holdings in Dynavax Technologies by 10.9% during the 2nd quarter. Vanguard Group Inc. now owns 2,024,666 shares of the biopharmaceutical company’s stock valued at $19,538,000 after buying an additional 199,004 shares in the last quarter. PointState Capital LP purchased a new position in Dynavax Technologies during the 2nd quarter valued at approximately $13,510,000. State Street Corp grew its holdings in Dynavax Technologies by 19.7% during the 2nd quarter. State Street Corp now owns 839,218 shares of the biopharmaceutical company’s stock valued at $8,099,000 after buying an additional 138,112 shares in the last quarter. Finally, C WorldWide Group Holding A S grew its holdings in Dynavax Technologies by 23.3% during the 3rd quarter. C WorldWide Group Holding A S now owns 823,825 shares of the biopharmaceutical company’s stock valued at $17,712,000 after buying an additional 155,610 shares in the last quarter. 70.61% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “$37.77 Million in Sales Expected for Dynavax Technologies Corporation (DVAX) This Quarter” was originally published by American Banking News and is the property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and republished in violation of international copyright & trademark legislation. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/05/37-77-million-in-sales-expected-for-dynavax-technologies-corporation-dvax-this-quarter.html.

Dynavax Technologies Company Profile

Dynavax Technologies Corporation is a clinical-stage immunotherapy company. The Company is focused on leveraging the body’s innate and adaptive immune responses through toll-like receptor (TLR) stimulation. Its product candidates are being investigated for use in multiple cancer indications, as a vaccine for the prevention of hepatitis B and as a disease modifying therapy for asthma.

Get a free copy of the Zacks research report on Dynavax Technologies (DVAX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies Corporation and related companies with MarketBeat.com's FREE daily email newsletter.